New Treatment for Adults with Acute Lymphoblastic Leukemia Approved by the FDA
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Category: AACR
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
A pair of studies published recently in journals of the American Association for Cancer Research bring to our attention...
This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists...
Yesterday, the American Association for Cancer Research (AACR) joined the American Cancer Society (ACS), the American Society of Clinical...
As President of the American Association for Cancer Research (AACR), Michael A. Caligiuri, MD, is a strong advocate for...
Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today Nearly 1.7 million new cancer cases and roughly 600,000...
The American Association for Cancer Research (AACR) has appeared in numerous publications lately, showcasing the breadth of our mission...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...